Drug Rule Targeting Pharma Liaisons Clears White House Review (1)

Nov. 19, 2020, 2:27 PMUpdated: Nov. 19, 2020, 3:25 PM

Release of a monumental drug policy that would scrap legal protections for certain payments between drugmakers and middlemen is imminent after it left executive review.

The Office of Management and Budget completed action on the rule Wednesday, according to its web site, which is a quick turnaround after it received the revived regulation from the Department of Health and Human Services Nov. 13.

The proposal was at one point the centerpiece of the Trump administration’s fight against high drug prices, but the HHS scrapped the rule last July because President Donald Trump feared it would raise premiums for seniors. Now, ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.